Mark P. Rubinstein PhD

Mark P. Rubinstein, PhD is an associate professor in the Division of Medical Oncology at Ohio State University and a researcher in the Pelotonia Institute for Immuno-Oncology at OSUCCC – James, where he also serves as a member of the Translational Therapeutics Program.

His laboratory is focused on understanding how the immune system functions and on applying this knowledge to the development of immune-based therapies to treat cancer. He seeks to bridge basic science and clinical medicine in order to develop novel strategies to treat cancer, including improving immune checkpoint therapy and adoptive cell therapy. He has ongoing collaborations with both industry and academic partners, and we are interested in new relationships that bring synergy and real-world solutions.

As part of our effort, we are studying lymphocyte biology and associated tumor immune inhibitory pathways. We are also studying how cytokines (such as IL-2 and IL-15) modulate immune responses, as well as developing novel protein- and antibody-based therapeutics.

Mark laboratory is also studying T-cell and antibody responses relevant to SARS-CoV2 vaccination or infection, including the impact of cancer therapies on the induction of long-lasting immunity. His work has been published in such peer-reviewed scientific journals as Science Translational Medicine, Lancet Oncology, and Cancer Research. I am also the co-holder of a patent for cytokine receptor genes and the use thereof to enhance therapy.